Authors:Rafael Bailón-Moreno, Encarnación Jurado-Alameda, Rosario Ruiz-Baños, Jean Courtial, and Evaristo Jiménez-Contreras
By a new fractal/transfractal geometry of the Unified Scientometric Model, it is possible to demonstrate that science presents
an oscillating or pulsing dynamic. It goes alternatively through two types of phases. Some phases are fractal, with crystalline
networks, where the Matthew effect clearly manifests itself with regard to the most notable actors and those that provide
the best contributions. The other phases are transfractal, with deformed, amorphous networks, in which the actors, considered
mediocre, present greater capacity to restructure the network than the more renowned actors. The result after any transfractal
deformation is a new crystalline fractal network. Behind this vision lies the Kuhn paradigms. As examples, the scientific
fields of surfactants and autism have been analysed.
Authors:Evaristo Jiménez-Contreras, Daniel Torres-Salinas, Rafael Moreno, Rosario Baños, and Emilio López-Cózar
The possibilities of the Response Surface Methodology (RSM) has been explored within the ambit of Scientific Activity Analysis.
The case of the system “Departments of the Area of Health Sciences of the University of Navarre (Spain)” has been studied
in relation to the system “Scientific Community in the Health Sciences”, from the perspective of input/output models (factors/response).
It is concluded that the RSM reveals the causal relationships between factors and responses through the construction of polynomial
mathematical models. Similarly, quasiexperimental designs are proposed, these permitting scientific activity to be analysed
with minimum effort and cost and high accuracy.
Authors:Clare Wilkins, Rafael G. dos Santos, Jordi Solá, Marc Aixalá, Pep Cura, Estefanía Moreno, Miguel Ángel Alcázar-Córcoles, Jaime E. C. Hallak, and José Carlos Bouso
Background and aims
Ibogaine is a natural alkaloid that has been used in the last decades as an adjuvant for the treatment of opiate withdrawal. Despite the beneficial results suggested by animal studies and case series, there is a lack of clinical trials to assess the safety and efficacy of ibogaine. Moreover, the majority of reports described cases of heroin-dependent individuals, with and without concomitant use of methadone, using high doses of ibogaine. Therefore, it is not clear if ibogaine at low doses could be used therapeutically in people on methadone maintenance treatments (MMT).
Case report of a female on MMT for 17 years who performed a self-treatment with several low and cumulative doses of ibogaine over a 6-week period.
The patient successfully eliminated her withdrawals from methadone with ibogaine. Each administration of ibogaine attenuated the withdrawal symptoms for several hours, and reduced the tolerance to methadone until all signs of withdrawal symptoms disappeared at the end of the treatment. No serious adverse effects were observed, and at no point did the QTc measures reach clinically significant scores. Twelve months after the treatment, she was no longer on MMT.
To our knowledge, this is the first case report describing an ibogaine treatment using low and cumulative doses in a person on MMT. Although preliminary, this case suggests that low and cumulative doses of ibogaine may reduce withdrawal symptoms in patients undergoing MMT.